Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 20 /PRNewswire/ -- The U.S.

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...

The anticoagulant medication dabigatran yielded similar results to warfarin for the prevention of cognitive decline in older adults with atrial fibrillation after two years of treatment, according to ...

WASHINGTON (March 19, 2017) -- Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation ...

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The parallel, open-label GIRAF trial randomly assigned ...

When it comes to preserving cognitive function in older patients with atrial fibrillation (AF) or flutter, the choice of oral anticoagulant doesn’t appear to matter much, according to the randomized ...

As expected, the European Medicines Agency (EMA) has extended the indications for the oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) to include treatment of deep vein thrombosis (DVT) ...

Alembic has received the Food and Drug Administration’s permission for Dabigatran Etexilate Capsules, 75 mg and 150 mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg. The approved ...

Three Groups Uncover New Gene Variants Affecting Heart Function Three separate research groups have identified a number of new genetic variants that influence heart rate and cardiac conduction. Two of ...